204 related articles for article (PubMed ID: 24572784)
1. MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation.
Tietje A; Li J; Yu X; Wei Y
Gene Ther; 2014 May; 21(5):468-75. PubMed ID: 24572784
[TBL] [Abstract][Full Text] [Related]
2. MICA/IL-12: A novel bifunctional protein for killer cell activation.
Tietje A; Yang X; Yu X; Wei Y
Oncol Rep; 2017 Mar; 37(3):1889-1895. PubMed ID: 28098874
[TBL] [Abstract][Full Text] [Related]
3. Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation.
Kotturi HS; Li J; Branham-O'Connor M; Stickel SL; Yu X; Wagner TE; Wei Y
Gene Ther; 2008 Oct; 15(19):1302-10. PubMed ID: 18463688
[TBL] [Abstract][Full Text] [Related]
4. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
5. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.
von Strandmann EP; Hansen HP; Reiners KS; Schnell R; Borchmann P; Merkert S; Simhadri VR; Draube A; Reiser M; Purr I; Hallek M; Engert A
Blood; 2006 Mar; 107(5):1955-62. PubMed ID: 16210338
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
7. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
8. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.
Belting L; Hömberg N; Przewoznik M; Brenner C; Riedel T; Flatley A; Polić B; Busch DH; Röcken M; Mocikat R
Eur J Immunol; 2015 Sep; 45(9):2593-601. PubMed ID: 26151313
[TBL] [Abstract][Full Text] [Related]
9. Four novel ULBP splice variants are ligands for human NKG2D.
Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
[TBL] [Abstract][Full Text] [Related]
10. An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation.
Zhu L; Zhao Z; Wei Y; Marcotte W; Wagner TE; Yu X
Int J Oncol; 2012 Aug; 41(2):661-9. PubMed ID: 22581115
[TBL] [Abstract][Full Text] [Related]
11. Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells.
Tu MM; Mahmoud AB; Wight A; Mottashed A; Bélanger S; Rahim MM; Abou-Samra E; Makrigiannis AP
Cancer Res; 2014 Jul; 74(14):3684-94. PubMed ID: 24802191
[TBL] [Abstract][Full Text] [Related]
12. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
[TBL] [Abstract][Full Text] [Related]
13. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
[TBL] [Abstract][Full Text] [Related]
14. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.
Vacca P; Martini S; Garelli V; Passalacqua G; Moretta L; Mingari MC
Eur J Immunol; 2013 Feb; 43(2):550-61. PubMed ID: 23192659
[TBL] [Abstract][Full Text] [Related]
15. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.
Deng W; Gowen BG; Zhang L; Wang L; Lau S; Iannello A; Xu J; Rovis TL; Xiong N; Raulet DH
Science; 2015 Apr; 348(6230):136-9. PubMed ID: 25745066
[TBL] [Abstract][Full Text] [Related]
16. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
17. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice.
Xia Y; Chen B; Shao X; Xiao W; Qian L; Ding Y; Ji M; Gong W
J Immunother; 2014 Jun; 37(5):257-66. PubMed ID: 24810637
[TBL] [Abstract][Full Text] [Related]
18. Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21.
Jiang B; Wu X; Li XN; Yang X; Zhou Y; Yan H; Wei AH; Yan W
Cell Immunol; 2014 Jul; 290(1):10-20. PubMed ID: 24859012
[TBL] [Abstract][Full Text] [Related]
19. [Expression and biological function of ULBP4 in Rosetta-gamiTMB(DE3) and mAb preparation].
Cao W; Hao ZY; Xi XY; Kong Y; Ma C; Cui LX; He W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Mar; 23(3):242-5. PubMed ID: 17343792
[TBL] [Abstract][Full Text] [Related]
20. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
